EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 2, 2010, Pages 434-442

  Van Laere, Koen ^a   Varrone, Andrea ^b   Booij, Jan ^c   Vander Borght, Thierry ^d   Nobili, Flavio ^e   Kapucu, Özlem L ^f   Walker, Zuzana ^g   Någren, Kjell ^h   Tatsch, Klaus ⁱ   Darcourt, Jacques ^j  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e UNIVERSITY OF GENOA   (Italy)

^f GAZI UNIVERSITY   (Turkey)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h Rigshospitalet   (Denmark)

ⁱ Municipal Hospital Karlsruhe   (Germany)

^j CENTRE ANTOINE LACASSAGNE   (France)

more..

Author keywords

Brain; D2 receptor; Dopamine; Parkinsonism; PET; SPECT

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; IODINE 123; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT;

HUNTINGTON CHOREA; HYPOPHYSIS ADENOMA; MEDICAL SOCIETY; NEUROIMAGING; NEUROTRANSMISSION; NUCLEAR MEDICINE; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WILSON DISEASE;

BRAIN; DOPAMINE; EUROPEAN UNION; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77949267716     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1265-z     Document Type: Review

References (37)

1. K Tatsch S Asenbaum P Bartenstein, et al. 2002 European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine transporter ligands Eur J Nucl Med Mol Imaging 29 BP30 BP35 10.1007/s00259-002-0814-5 1:STN:280:DC%2BD38nntl2rtQ%3D%3D 12436496 (Pubitemid 34439333)
2. Society of Nuclear Medicine Brain Imaging Council 1996 Ethical clinical practice of functional brain imaging J Nucl Med 37 1256 1259
3. PH Elsinga K Hatano K Ishiwata 2006 PET tracers for imaging of the dopaminergic system Curr Med Chem 13 2139 2153 10.2174/092986706777935258 1:CAS:528:DC%2BD28XnslOksrY%3D 16918344 (Pubitemid 44132606)
4. J Mukherjee ZY Yang MK Das T Brown 1995 Fluorinated benzamide neuroleptics - III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3- [18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer Nucl Med Biol 22 283 296 10.1016/0969-8051(94)00117-3 1:CAS:528:DyaK2MXlvFGls74%3D 7627142
5. M Schreckenberger S Hagele T Siessmeier, et al. 2004 The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism Eur J Nucl Med Mol Imaging 31 1128 1135 10.1007/s00259-004-1465-5 1:CAS:528:DC%2BD2cXmtFWks7s%3D 15042325
6. L Farde E Ehrin L Eriksson, et al. 1985 Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography Proc Natl Acad Sci U S A 82 3863 3867 10.1073/pnas.82.11. 3863 1:CAS:528:DyaL2MXkvVChsb4%3D 3873656 (Pubitemid 15246452)
7. KP Lindsey SJ Gatley SJ 2006 Applications of clinical dopamine imaging Neuroimaging Clin N Am 16 553 573 10.1016/j.nic.2006.06.003 17148019 (Pubitemid 44828753)
8. B Ravina D Eidelberg JE Ahlskog, et al. 2005 The role of radiotracer imaging in Parkinson disease Neurology 64 208 215 1:STN:280: DC%2BD2M%2FktFSnsA%3D%3D 15668415
9. S Thobois M Jahanshahi S Pinto R Frackowiak P Limousin-Dowsey 2004 PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences Neuroimage 23 1 16 10.1016/j.neuroimage.2004.04.039 1:STN:280:DC%2BD2cvhvFymtQ%3D%3D 15325346 (Pubitemid 39119429)
10. J Booij RJ Knol 2007 SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease Parkinsonism Relat Disord 13 Suppl 3 S425 S428 10.1016/S1353-8020(08)70042-7 18267276 (Pubitemid 351215280)
11. C Halldin B Gulyas O Langer L Farde 2001 Brain radioligands - state of the art and new trends Q J Nucl Med 45 139 152 1:STN:280:DC%2BD3MvivVGhtw%3D%3D 11476163
12. LH Pinborg C Videbaek GM Knudsen, et al. 2000 Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion Synapse 36 322 329 10.1002/(SICI)1098-2396(20000615)36:4<322:: AID-SYN9>3.0.CO;2-W 1:CAS:528:DC%2BD3cXjtFSmurk%3D 10819910 (Pubitemid 30257317)
13. GM Knudsen M Karlsborg G Thomsen, et al. 2004 Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy Eur J Nucl Med Mol Imaging 31 1631 1638 10.1007/s00259-004-1578-x 1:CAS:528:DC%2BD2cXhtVCmurrN 15583914 (Pubitemid 40104609)
14. M Ghaemi R Hilker J Rudolf J Sobesky WD Heiss 2002 Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging J Neurol Neurosurg Psychiatry 73 517 523 10.1136/jnnp.73.5.517 1:STN:280:DC%2BD38njvVSktQ%3D%3D 12397143 (Pubitemid 35246803)
15. C Oyanagi Y Katsumi T Hanakawa, et al. 2002 Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography J Neuroimaging 12 316 324 10.1111/j.1552-6569.2002.tb00139.x 12380478
16. YJ Kim M Ichise JR Ballinger, et al. 2002 Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP Mov Disord 17 303 312 10.1002/mds.10042 11921116 (Pubitemid 36041299)
17. A Antonini KL Leenders P Vontobel, et al. 1997 Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease Brain 120 Pt 12 2187 2195 10.1093/brain/120.12.2187 9448574 (Pubitemid 28014595)
18. W Pirker S Asenbaum S Wenger, et al. 1997 Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease J Nucl Med 38 1711 1717 1:CAS:528:DyaK2sXns1yiu7Y%3D 9374338
19. M Plotkin H Amthauer S Klaffke, et al. 2005 Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients J Neural Transm 112 677 692 10.1007/s00702-004-0208-x 1:STN:280:DC%2BD2M7ps1SnsA%3D%3D 15375677 (Pubitemid 40591200)
20. L Pani L Pira G Marchese 2007 Antipsychotic efficacy: relationship to optimal D2-receptor occupancy Eur Psychiatry 22 267 275 10.1016/j.eurpsy.2007. 02.005 17419008 (Pubitemid 47096691)
21. J Scherer K Tatsch J Schwarz W Oertel MC Kirsch M Albus 1994 Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics Biol Psychiatry 36 627 629 10.1016/0006-3223(94)90076-0 1:STN:280:DyaK2M7jsVymsw%3D%3D 7833430
22. E Klemm F Grunwald S Kasper, et al. 1996 [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics Am J Psychiatry 153 183 190 1:STN:280:DyaK287lsF2hug%3D%3D 8561197
23. M Ichise H Toyama L Fornazzari JR Ballinger JC Kirsh 1993 Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease J Nucl Med 34 1274 1281 1:STN:280:DyaK3szhs1WlsA%3D%3D 8326384
24. N Ginovart A Lundin L Farde, et al. 1997 PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease Brain 120 Pt 3 503 514 10.1093/brain/120.3.503 9126061 (Pubitemid 27153642)
25. WH Oertel K Tatsch J Schwarz, et al. 1992 Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease Ann Neurol 32 743 748 10.1002/ana.410320607 1:STN:280:DyaK3s7htFKqug%3D%3D 1471864
26. C Muhr 2006 Positron emission tomography in acromegaly and other pituitary adenoma patients Neuroendocrinology 83 205 210 10.1159/000095529 1:CAS:528:DC%2BD28XhtV2hu7vN 17047384 (Pubitemid 44578873)
27. WD Heiss K Herholz 2006 Brain receptor imaging J Nucl Med 47 302 312 1:CAS:528:DC%2BD28Xhslantrk%3D 16455637
28. JO Rinne J Hietala U Ruotsalainen, et al. 1993 Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride J Cereb Blood Flow Metab 13 310 314 1:CAS:528:DyaK3sXisVyhsLk%3D 8436624
29. AA Lammertsma SP Hume 1996 Simplified reference tissue model for PET receptor studies Neuroimage 4 153 158 10.1006/nimg.1996.0066 1:STN:280:DyaK1c%2FgsFeltw%3D%3D 9345505 (Pubitemid 27024284)
30. P Calvini G Rodriguez F Inguglia A Mignone UP Guerra F Nobili 2007 The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation Eur J Nucl Med Mol Imaging 34 1240 1253 10.1007/s00259-006-0357-2 17287959 (Pubitemid 47290660)
31. G Popperl P Radau R Linke K Hahn K Tatsch 2005 Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism Nucl Med Commun 26 39 43 10.1097/00006231-200501000-00007 15604946 (Pubitemid 40189623)
32. PE Radau R Linke PJ Slomka K Tatsch 2000 Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism J Nucl Med 41 220 227 1:STN:280:DC%2BD3c7ltVyisw%3D%3D 10688103
33. IG Zubal M Early O Yuan D Jennings K Marek JP Seibyl 2007 Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients J Nucl Med 48 857 864 10.2967/jnumed.106.037432 17504864 (Pubitemid 46909911)
34. R Buchert G Berding F Wilke, et al. 2006 IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies Eur J Nucl Med Mol Imaging 33 1073 1083 10.1007/s00259-006-0067-9 1:CAS:528:DC%2BD28XotVynu74%3D 16614812 (Pubitemid 44215673)
35. M Slifstein DR Hwang D Martinez, et al. 2006 Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET J Nucl Med 47 313 319 1:CAS:528:DC%2BD28XhslantrY%3D 16455638
36. NP Verhoeff EB Sokole M Stabin, et al. 1993 Dosimetry of iodine-123 iodobenzamide in healthy volunteers Eur J Nucl Med 20 747 752 1:CAS:528:DyaK2cXhvVKitLo%3D 8223767
37. JR Votaw MS Ansari NS Mason, et al. 1995 Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand J Nucl Med 36 1316 1321 1:CAS:528:DyaK2MXntFSjurs%3D 7790962